List of Excipients in Branded Drug RAVICTI

« Back to Dashboard

RAVICTI Excipient Strategy and Commercial Opportunities

Last updated: September 23, 2026

RAVICTI is an oral liquid containing glycerol phenylbutyrate for chronic nitrogen control in patients with urea cycle disorders. Its principal formulation advantage is the absence of conventional inactive excipients: the marketed product is essentially an active pharmaceutical ingredient delivered as a liquid, with packaging and administration hardware carrying much of the product value. Commercial opportunities therefore center on dosing accuracy, pediatric usability, feeding-tube administration, stability, taste management, manufacturing efficiency, and differentiated follow-on products rather than on traditional excipient substitution.

What is RAVICTI and how is it regulated?

RAVICTI contains glycerol phenylbutyrate, a nitrogen-scavenging prodrug metabolized to phenylacetate. Phenylacetate conjugates with glutamine, producing phenylacetylglutamine, which is excreted in urine and removes two nitrogen atoms per molecule (FDA, 2024).

Product attribute	RAVICTI profile
Active ingredient	Glycerol phenylbutyrate
Dosage form	Oral liquid
Strength	1.1 g/mL glycerol phenylbutyrate
FDA pathway	New drug application
Original FDA approval	2013
Current use	Chronic management of patients with urea cycle disorders
Patient populations	Adults and pediatric patients aged 2 months and older, subject to labeling limitations
Original developer	Hyperion Therapeutics
Commercial ownership history	Hyperion, Horizon Pharma, then Amgen following its acquisition of Horizon
Administration	Oral dosing using a calibrated syringe; may be administered directly or mixed with specified foods or liquids under the prescribing information
Storage	Controlled room-temperature storage under the approved label

RAVICTI is an orphan-disease product. The commercial model depends on long-term treatment, specialist prescribing, reimbursement support, and reliable pediatric administration rather than high unit volume.

What excipients are used in RAVICTI?

RAVICTI is listed with no inactive ingredients in the FDA labeling. Glycerol phenylbutyrate is the active pharmaceutical ingredient and the liquid vehicle is intrinsic to the drug substance formulation rather than a conventional excipient system (FDA, 2024).

This creates an unusual excipient strategy:

1. There is no standard solvent, buffer, preservative, sweetener, surfactant, or suspending agent to replace.
2. Excipient-related differentiation must focus on administration, palatability, packaging, and stability.
3. A follow-on developer may have limited freedom to alter the formulation without changing dose delivery, tolerability, compatibility, or comparative performance.
4. The absence of inactive ingredients can simplify qualitative and quantitative sameness analysis for a conventional generic application.

Why the no-excipient formulation matters commercially

A minimal formulation reduces several technical risks:

• Preservative-related toxicity or hypersensitivity.
• pH adjustment and buffer compatibility problems.
• Precipitation or phase separation caused by aqueous excipients.
• Excipient exposure in infants and medically fragile patients.
• Extractables and leachables associated with complex container systems.
• Variability from suspending agents or viscosity modifiers.

The trade-off is that the formulation has fewer tools for taste masking, viscosity control, and dose-delivery optimization. RAVICTI therefore shifts product performance from excipient engineering to the active liquid, bottle, syringe, instructions, and administration workflow.

What formulation and excipient opportunities exist for RAVICTI competitors?

The strongest opportunities are not conventional “me-too” excipient substitutions. They are differentiated delivery products that improve use without materially changing systemic exposure.

Taste and odor management

Phenylbutyrate products can create administration challenges because of odor and taste. A competing product could explore:

• Flavor systems compatible with the active liquid.
• Microencapsulation or coating technologies.
• Dose-unit packaging that reduces exposure to odor.
• Oral films or dispersible dosage forms.
• Measured dose delivery that limits contact with the oral cavity.
• Food-compatible presentations for pediatric use.

Any flavor or taste-masking approach must preserve the conversion of glycerol phenylbutyrate to active metabolites and must not introduce clinically relevant dose variability.

Pediatric administration

Urea cycle disorders often require treatment from infancy. Product developers can target:

• Lower-volume presentations.
• Unit-dose containers.
• Oral syringes with integrated dose markings.
• Anti-spill bottle designs.
• Caregiver-friendly adapters.
• Single-hand dosing systems.
• Packaging that reduces repeated bottle opening.

The commercial value of these features is high because treatment is chronic and caregivers may administer multiple doses each day.

Feeding-tube compatibility

A formulation or device that performs consistently through commonly used enteral tubes could differentiate from the reference product. Development work would need to address:

• Tube adsorption.
• Residual volume.
• Flushing requirements.
• Compatibility with tube materials.
• Dose recovery.
• Clogging risk.
• Stability after transfer into a syringe or feeding container.

A feeding-tube claim would be more commercially defensible if supported by standardized compatibility studies and incorporated into labeling.

Alternative dosage forms

Potential follow-on formats include:

Format	Commercial rationale	Main technical barrier
Ready-to-use unit dose	Reduces measuring errors and contamination	Packaging cost and dose flexibility
Oral film	Could improve portability and taste	High drug loading and dose uniformity
Softgel or capsule	May reduce taste exposure	Pediatric swallowing and dose titration
Granule or powder	Improves shelf-life and transport	Reconstitution and dose accuracy
Prefilled oral syringe	Simplifies caregiver administration	Stability and device compatibility
Enteral-specific formulation	Supports tube-fed patients	Recovery and tube-material studies

The most practical opportunities are likely to involve packaging and dosing systems rather than a radically different dosage form. RAVICTI dosing is individualized according to dietary protein intake, residual enzyme activity, growth, and biochemical monitoring. A rigid fixed-dose product could reduce clinical flexibility.

How does RAVICTI compare with other nitrogen-scavenging products?

RAVICTI competes primarily with sodium phenylbutyrate products and, in selected clinical settings, alternative nitrogen-scavenging therapies.

Product	Active ingredient	Form	Key commercial distinction
RAVICTI	Glycerol phenylbutyrate	Oral liquid	Lower sodium burden and potentially improved tolerability versus sodium phenylbutyrate
BUPHENYL	Sodium phenylbutyrate	Tablets and granules	Established alternative, but sodium load and administration burden affect use
PHEBURANE	Sodium phenylbutyrate	Oral granules	Taste-masking and administration differentiation
AMMONUL	Sodium benzoate plus sodium phenylacetate	Intravenous	Acute inpatient treatment, not a direct chronic oral substitute
Carglumic acid	Carglumic acid	Oral dispersible tablet	Used in selected hyperammonemia settings, including specific metabolic defects

Glycerol phenylbutyrate provides a lower-sodium alternative to sodium phenylbutyrate. That distinction supports premium pricing, chronic adherence arguments, and use in patients for whom sodium exposure is clinically undesirable. Sodium phenylbutyrate products remain important price competitors because they can be available in multiple dosage forms and may have lower acquisition costs.

What FDA exclusivity and patent issues affect RAVICTI?

RAVICTI received FDA approval in 2013 for a rare metabolic disease. Orphan-drug exclusivity would have applied for seven years from approval for the protected indication under the Orphan Drug Act. That period does not prevent all forms of competition after expiry, and it does not eliminate separate patent or regulatory protections.

The relevant exclusivity categories are:

Protection	Relevance to RAVICTI
Orphan-drug exclusivity	Seven-year protection for the approved orphan indication, subject to statutory exceptions
New chemical entity exclusivity	Potentially relevant at original approval, depending on FDA regulatory classification
Pediatric exclusivity	Could extend listed patent or exclusivity periods if granted after an FDA pediatric study request
Orange Book patents	May include approved-use, formulation, method, or other listed patents
Patent-term adjustment or extension	May affect individual patent expiry dates
Regulatory exclusivity for follow-on products	Depends on the applicant’s pathway and the reference product’s current status

A current patent analysis must distinguish between patents that cover glycerol phenylbutyrate generally, patents that cover a particular liquid formulation, patents directed to manufacturing processes, and patents listed for approved methods of use. The FDA Orange Book, issued patents, terminal disclaimers, patent-term adjustments, and litigation records should be reviewed together before evaluating generic entry timing (FDA, 2024a).

How strong is the RAVICTI patent estate?

The product’s commercial defensibility does not depend only on composition claims. Potentially relevant layers include:

• Glycerol phenylbutyrate composition claims.
• Liquid formulation claims.
• Manufacturing and purification claims.
• Stability claims.
• Dosing regimens for urea cycle disorders.
• Pediatric or age-specific administration claims.
• Combination or food-administration claims.
• Container and dosing-device claims.

The absence of conventional excipients may weaken a narrow excipient-combination strategy because there is less formulation complexity to claim. It can strengthen manufacturing and product-consistency arguments if the active liquid requires controlled impurity levels, stereochemical control, or specialized filling operations.

When could generic or follow-on competition enter?

A conventional generic applicant may pursue an abbreviated new drug application if FDA determines that the product can be adequately characterized through pharmaceutical equivalence, bioequivalence, and applicable quality controls. The absence of inactive ingredients may reduce some formulation-comparison complexity, but it does not eliminate development barriers.

Key generic risks include:

• Demonstrating equivalent concentration and dose delivery.
• Establishing comparable impurity and degradation profiles.
• Reproducing container-closure performance.
• Showing consistent syringe dosing.
• Addressing the active liquid’s physical and chemical stability.
• Resolving Orange Book patent certifications.
• Managing method-of-use patents.
• Establishing adequate labeling for a rare pediatric disease.

A Paragraph IV certification could trigger Hatch-Waxman litigation if an applicant asserts that listed patents are invalid, unenforceable, or not infringed. A notice of Paragraph IV certification can create a 30-month stay of FDA approval in qualifying circumstances after timely patent litigation by the NDA holder or patent owner (Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355).

A generic launch could occur through several scenarios:

1. At-risk launch after a court ruling or settlement permits entry.
2. Entry after all relevant listed patents expire.
3. Negotiated entry under a settlement agreement.
4. Limited launch after a patent is held invalid or not infringed.
5. Non-infringing entry using a revised label that omits protected methods of use, where legally and regulatorily viable.

No biosimilar pathway applies. RAVICTI is a small-molecule drug, not a biologic. Competitive entry would be evaluated under generic-drug and hybrid-drug pathways rather than under the Biologics Price Competition and Innovation Act.

What commercial opportunities exist for excipient and packaging suppliers?

The strongest supplier opportunities are adjacent to the active formulation.

High-value opportunity areas

• Oral dosing syringes with improved low-volume accuracy.
• Bottle adapters designed for viscous or oily liquids.
• Low-sorption syringe and tube materials.
• Child-resistant, caregiver-friendly packaging.
• Unit-dose liquid containers.
• Odor-reducing secondary packaging.
• Stability-enhancing amber containers.
• Automated filling systems for high-viscosity liquids.
• Extractables and leachables testing.
• Enteral-device compatibility testing.
• Digital dose-recording systems linked to specialty pharmacy support.

A supplier that can demonstrate lower residual volume, improved dose recovery, or better administration accuracy may create more value than a supplier offering a conventional flavor or preservative.

Manufacturing barriers

The manufacturing process must control:

• Active concentration.
• Water content.
• Degradation products.
• Trace impurities.
• Batch-to-batch viscosity.
• Fill-volume accuracy.
• Container interaction.
• Long-term and in-use stability.

A follow-on manufacturer may need specialized equipment for handling an oily liquid and for filling a high-value orphan product in relatively small commercial batches. These requirements can raise cost of goods and limit the number of credible entrants.

What is the revenue exposure and competitive outlook?

RAVICTI’s revenue base is concentrated in a small population with a high annual treatment value. Commercial exposure is driven by:

• Patient retention.
• Diagnosis rates for urea cycle disorders.
• Pediatric survival and transition into chronic treatment.
• Reimbursement approvals.
• Specialist-center prescribing.
• Competition from sodium phenylbutyrate.
• Generic or authorized-generic entry.
• Manufacturing continuity.

The product has a defensible commercial position when it delivers lower sodium exposure, better tolerability, and simpler chronic administration than sodium phenylbutyrate. That position is vulnerable if a competing product materially improves taste, reduces dose volume, offers lower acquisition cost, or secures broad payer coverage.

For Amgen, the primary business risk is not biosimilar substitution. It is small-molecule generic erosion combined with payer pressure and conversion to lower-cost sodium phenylbutyrate products. For potential entrants, the most attractive strategy is a differentiated oral delivery product with clear pediatric and enteral-use advantages.

What should an RAVICTI lifecycle strategy prioritize?

A commercially credible lifecycle program should prioritize:

1. A validated low-volume dosing system.
2. Pediatric and feeding-tube administration data.
3. Packaging that limits odor and dosing errors.
4. A product with flexible titration.
5. Manufacturing controls that support a narrow impurity profile.
6. A patent strategy covering device, formulation, manufacturing, and use.
7. Evidence that improves adherence or reduces caregiver burden.
8. Reimbursement data showing lower total treatment burden.
9. A regulatory pathway aligned with the intended product claim.
10. Geographic filing coverage in the United States, Europe, Japan, and other rare-disease markets.

An excipient-only reformulation is unlikely to create a strong commercial moat because the reference product has no listed inactive ingredients. A delivery-system, administration, or manufacturing strategy has greater potential.

Key Takeaways

• RAVICTI is a glycerol phenylbutyrate oral liquid approved for chronic management of urea cycle disorders.
• The FDA label lists no inactive ingredients, making conventional excipient substitution a limited opportunity.
• The highest-value formulation opportunities involve taste management, pediatric dosing, feeding-tube compatibility, and unit-dose packaging.
• Generic competition would likely focus on pharmaceutical equivalence, dose accuracy, container performance, and patent certifications.
• RAVICTI is not exposed to biosimilar competition because it is a small-molecule drug.
• The product competes with sodium phenylbutyrate products, which retain cost and dosage-form advantages.
• Packaging, dosing devices, manufacturing controls, and administration evidence may provide stronger differentiation than a new excipient system.
• Patent and exclusivity conclusions require review of the current FDA Orange Book, issued patents, patent-term calculations, and Paragraph IV litigation records.

FAQs

Can RAVICTI be reformulated with flavoring agents?

Potentially, but any flavoring system must preserve stability, dose accuracy, metabolite formation, and labeled administration conditions. A flavor-enhanced product would need regulatory support and may require a new formulation strategy rather than a simple commercial variation.

Is RAVICTI an excipient-free drug product?

The FDA labeling identifies no inactive ingredients. The product is an oral liquid in which glycerol phenylbutyrate is the active ingredient and the formulation does not rely on a conventional excipient package.

What is the best generic strategy for glycerol phenylbutyrate?

The most direct strategy is an equivalent oral liquid with matching strength, dose delivery, container performance, and labeling, subject to FDA requirements and applicable patent certifications. A differentiated product could instead target pediatric administration, enteral-tube use, or odor reduction.

Can RAVICTI be replaced by sodium phenylbutyrate?

Sodium phenylbutyrate is a therapeutic alternative in appropriate patients, but substitution requires clinical judgment. The products differ in active ingredient, sodium exposure, dosing burden, tolerability, and formulation.

Are device patents commercially important for RAVICTI?

Yes. Because the drug has no conventional inactive-ingredient system, dosing syringes, bottle adapters, unit-dose containers, and enteral-delivery components may carry greater lifecycle value than traditional excipient claims.

References

Amgen Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Food and Drug Administration. (2013). RAVICTI approval letter and prescribing information, NDA 203284.

Food and Drug Administration. (2024). RAVICTI (glycerol phenylbutyrate) prescribing information. U.S. Department of Health and Human Services.

Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

U.S. Congress. (2023). Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.